Corryn Biotechnologies is a spin-out company based on the research of Dr Luke Burke, who completed his PhD at Swansea University in 2015. Luke’s research was based around advanced materials and nanotechnology, and the ways in which they can change wound-care for the better.
As a Type 1 diabetic, Dr Burke has often had to deal with the leg and foot ulcers that are caused by his condition. His view has always been that, although there are some interesting dressing materials on the market, they are all based around the core approach of ‘applying fabric to a wound’. These methods, however tried and tested, often come with challenges, mainly keeping the wounds sterile whilst enabling them to heal quickly and naturally.
Having researched it further, Luke decided to investigate resorbable materials, regenerative medicine, and nanotechnology. He worked in the industry using breakthrough, cutting edge technology and techniques, and realised their benefit to a range of medical scenarios. During this time, Luke also understood the difficulties of producing, sterilising, and packaging micro and nano-fibrous materials, and the poor clinical outcomes and high expenses currently facing healthcare systems around the world.
That is where his innovation comes in! Luke has designed a hand-held device that enables the user to apply micro and nano-fibrous materials directly onto wounds, without having to touch the area at all. It works with a high voltage electrical charge that enables the materials to be deposited directly onto the wound site in a painless and straightforward manner. It also means healing can happen quickly, safely, and minimises the dangers that surround wound-care.
Luke heard about AgorIP through Swansea University and came to us for assistance with his innovation. The scheme is supported by the Welsh Government and the European Regional Development Fund, and through that Luke was provided with Technology Transfer support to fund device prototyping, as well as helping protect his intellectual property by filing for a patent.
Through the support given by AgorIP, Corryn Biotechnologies has secured an Enterprise Fellowship through the Royal Academy of Engineering, which alongside AgorIP’s direct support has enabled the company to hit some major milestones, including the production of prototypes, the validation of the device’s technology, as well as connections with potential clinical partners, investors, and further research leads.
We look forward to seeing where Dr Burke’s innovation takes him!
You can find out more at their website: www.corryn.co.uk
Or contact them for more information at: [email protected]